Skip to main content Skip to main content
Go to homepage

Privigen Randomized Study for Pediatric CIDP

Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP


See complete study information on

Who May Qualify?:

Male or female patients 2 to <17 years of age with confirmed or possible chronic inflammatory demyelinating polyneuropathy (CIDP)

Who Does Not Qualify:

Patients with:

  • History or family history of inherited neuropathy
  • Diagnosed developmental delay or regression
  • History of thrombotic episode
  • Known or suspected hypersensitivity to Privigen
  • Known allergic or other severe reactions to blood products
  • Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
  • Pregnant or breastfeeding mother
Interested in participating?
We are currently recruiting
Study Sponsor:

CSL Behring

Full IRB Study Title:
Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Hilary Tonni, Rebecca D. Considine Research Institute: 330-543-4734

Lead Investigator
Ian Rossman, MD, PhD

Pediatric Neurologist
NeuroDevelopmental Science CenterPediatric Neuromuscular ClinicPediatric NeurologyMitochondrial Center

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.